Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing fibromyalgia pain. These findings highlight the ongoing gap between widespread patient use of CBD for fibromyalgia and the clinical evidence supporting that use. Clinicians should communicate this uncertainty clearly when patients ask about CBD as a pain management strategy for fibromyalgia.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides the first rigorous evidence evaluating CBD’s efficacy in fibromyalgia, addressing a significant gap given widespread off-label use without established clinical benefit. The findings establish whether CBD represents a viable pharmacological option for fibromyalgia patients who frequently face limited treatment alternatives and tolerance issues with conventional analgesics. This evidence is critical for informing clinical practice guidelines and patient counseling regarding CBD’s actual therapeutic value in this chronic pain condition.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomized controlled trial addresses a significant evidence gap in cannabidiol use for fibromyalgia, a condition where patients often seek cannabis-based therapies despite limited rigorous data. While the study’s double-blind, placebo-controlled design is methodologically sound, several factors warrant cautious interpretation: single-centre recruitment may limit generalizability, the specific CBD dose and formulation details appear truncated in the abstract, and fibromyalgia’s heterogeneous presentation means responders and non-responders may be clinically meaningful subgroups not apparent in aggregate outcomes. Additionally, we cannot yet assess whether observed effects exceed placebo by margins clinically meaningful to patients or whether concurrent medications and non-pharmacological therapies were adequately controlled. For clinical practice, this study should inform shared decision-making conversations where CBD is being considered for fibromyalgia, helping providers transparently discuss what the evidence actually shows rather than relying on patient reports or anecdotal enthusiasm, while emphasizing that any trial of CBD warrants